insitro and Bristol Myers Squibb have announced the next phase of their collaboration to discover novel therapies for amyotrophic lateral sclerosis (ALS), leveraging insitro’s AI-enabled ChemML™ platform to design new molecules targeting a novel ALS target identified in the first biological evaluation phase. The one-year extension may bring up to $20 million in new funding, therapeutic exceeding $2 billion through discovery, development, regulatory, commercial milestones, and royalties. “Our collaboration with Bristol Myers Squibb has uncovered novel targets with potential to address the underlying biology of ALS,” said Daphne Koller, Ph.D., founder and CEO of insitro.
Also Read: Microchip Unveils First 3nm Switchtec Gen 6 PCIe® Switches
“We are now moving into the next phase – turning these discoveries into medicines. With ChemML, our end-to-end drug design platform, we can translate novel targets into advanced small-molecule leads rapidly, leveraging a differentiated set of capabilities that spans AI-driven modeling, medicinal chemistry, and structural biology. While advancing these initial drug candidates, we will continue our efforts to identify additional new targets that have the potential to be disease-modifying. Our aim remains unwavering: to deliver truly transformative treatments that enable people with ALS to live longer.” With high compute infrastructure of 192 H100 GPUs, ChemML™ rapidly designs and optimizes small molecules, that demonstrate motor neuron survival and reversal of downstream ALS pathology, according to Philip Tagari, CSO, insitro.